Total trials
83
Active
2
Phase 3
6
Total enrollment
24,583
Pipeline matrix
Showing 5 of 5 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Sodium monofluorophosphate dentifrice | — | — | — | — | 2 | ||
| Test Stannous Fluoride Dentifrice | — | — | — | — | — | 1 | |
| Stannous Fluoride Dentifrice | — | — | — | 7 | |||
| 0.76% Sodium Monofluorophosphate Dentifrice | — | — | — | — | 4 | ||
| 0.454% Stannous Fluoride Dentifrice | — | — | — | — | 4 |
Next readouts
- 2025-10-31
- 2025-12-07
Top conditions
- Gingivitis22
- Dentin Sensitivity9
- Dental Plaque5
- Plaque4
- Healthy4
- Caries4
- Dentinal Hypersensitivity2
- Healthy Subjects2
Frequently asked questions about Procter and Gamble
- How many clinical trials does Procter and Gamble have on ClinicalTrials.gov?
- Procter and Gamble is listed as the lead sponsor on 83 clinical trials in ClinicalTrials.gov, 2 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Procter and Gamble's trials are in Phase 3?
- 6 of Procter and Gamble's trials are in Phase 3, spread across 5 active drug programs.
- What therapeutic areas does Procter and Gamble focus on?
- Procter and Gamble's most-studied conditions on ClinicalTrials.gov are Gingivitis, Dentin Sensitivity, Dental Plaque, Plaque, Healthy.
- When are Procter and Gamble's next clinical trial readouts?
- Procter and Gamble has 2 upcoming primary-completion readouts tracked here; the soonest is “Evaluating Gingivitis and Systemic Biomarkers”, expected around 2025-10-31.